Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 13, 2021 3:21pm
148 Views
Post# 33196449

RE:RE:RE:RE:Moving on

RE:RE:RE:RE:Moving on
I posted this earlier the article goes on also suggesting combination therapies as another approach to bypass the MDR.
This article published yesterday emphasized the urgent need for a targeted drug therapy such as PDC for among others metastatic breast cancer due to multidrug resistance, Thus far a combination of anticancer drugs has been used as standard chemotherapy treatment although this approach has been showing success for early stages of cancers eventually the chemotherapeutic agents flow out of the cancer cells and patient develop multi drug resistance to common anti-cancer drugs. Also chemotherapy mostly involves use of hydrophobic drugs that can be rapidly cleared from the tumor site due to their small molecular weight. This can result in lower circulation half-life and sub-therapeutic concentrations at the tumor site. To remedy the problem to certain extent a targeted anticancer drug delivery into cancer cells could result in higher dosage of the agent thus mitigate the multidrug resistance issue.
 




<< Previous
Bullboard Posts
Next >>